Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of fremanezumab for prevention of cluster headache
MOH_2017-05-29_000389Phase 3Recruiting
- Sponsor
- Teva Pharmaceutical Industries
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind trial of fremanezumab in Cluster Headache (CH) (3 arms), sponsored by Teva Pharmaceutical Industries. Primary endpoint: Long-term safety. Started Feb 2017; status: recruiting.
02
Drugs
fremanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on MOH_2017-05-29_000389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-29_000389.